ReNeuron Group plc ReNeuron featured in BBC documentary
15 February 2017 - 6:00PM
RNS Non-Regulatory
TIDMRENE
ReNeuron Group plc
15 February 2017
15 February 2017 AIM: RENE
RNS REACH
ReNeuron Group plc
("ReNeuron" or the "Company")
ReNeuron featured in BBC documentary "Andrew Marr: My Brain and
Me"
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces that its CTX cell
therapy candidate has been featured in the BBC documentary, "Andrew
Marr: My Brain and Me", which was screened for the first time last
night on BBC2.
In the programme, the well-known broadcaster and political
journalist Andrew Marr documents his mission to explore pioneering
stroke treatments after suffering a life-threatening stroke four
years ago, which has left him with reduced movement in his left
arm, hand and leg.
Professor Keith Muir, the Principal Investigator of ReNeuron's
Phase II clinical trial in stroke disability, is featured in the
programme explaining the role of stem cells and how they are being
used as a potential treatment for patients living with the chronic
consequences of a stroke. The programme also follows the progress
of a stroke patient who took part in ReNeuron's Phase II clinical
trial.
On 5 December 2016, ReNeuron announced positive Phase II data
from its clinical trial of its CTX cell therapy candidate for
stroke disability. As a result of the positive data from the trial,
the Company intends to apply to the US and European regulatory
authorities to commence a randomised, placebo-controlled, pivotal
clinical trial in patients who are living with disability
post-stroke.
In addition to last night's national screening, the programme
will air on BBC2 on 16 February 2017 at 11.15pm (England) and on 17
February 2017 at 12.05am (Wales).
The programme is also available to view on iPlayer at the
following link:
http://www.bbc.co.uk/iplayer/episode/b08flqbv/andrew-marr-my-brain-and-me
ENQUIRIES:
ReNeuron +44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for motor disability as a result of stroke, for
critical limb ischaemia and for the blindness-causing disease,
retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALIFVRFDIELID
(END) Dow Jones Newswires
February 15, 2017 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024